Annual Report and Accounts, and notice of AGM

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Annual Report and Accounts for the year ended 30 June 2017 is now available on the Group’s website at www.clinigengroup.com.

Copies of the Annual Report and Accounts will be posted to shareholders later today.

The Group will hold its Annual General Meeting (‘AGM’) on 28 November 2017 at 10.00am at Instinctif Partners’ offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer, will give a presentation at the AGM. The slides will be made available on the Group’s website after the meeting. No new material information will be provided.

- Ends -

CONTACT DETAILS

Clinigen Group plc
Peter Allen, Chairman
Matt Parish, Head of Investor Relations
Tel: +44 (0) 1283 495010

Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Tel: +44 (0) 20 7260 1000

RBC Capital Markets – Joint Broker
Marcus Jackson / Elliot Thomas / Jack Wood
Tel: +44 (0) 20 7653 4000

Instinctif Partners
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell
Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.  

Clinical Trial Services

Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.

Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides ‘on-demand’ access globally to medicines which remain unlicensed at the point of care.

Commercial Medicines

The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

For more information on Clinigen, please visit www.clinigengroup.com